Drugs / Passiflora incarnata
last change Dec 2019 re-read 2 minutes ago

Passiflora incarnata

Developed for
substance withdrawal syndrome
Investigated by
Nutricion Medica S.L.

Trials 1 · a red edge is where a trial was stopped

20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT03780595 Sep 2018 → Jun 2019 substance withdrawal syndrome Nutricion Medica S.L. Unknown No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/31 trial
Phase 2/3 NCT02065843 Comparator Mar → Apr 2014 impacted teeth, multiple Federal University of Sergipe Completed No outcome recorded
Phase 32 trials
Phase 3 NCT01695616 Comparator Aug 2013 → Aug 2014 Ache Laboratorios Farmaceuticos S.A. Withdrawn No outcome recorded
Phase 3 NCT01665170 Comparator May → Aug 2012 Pascoe Pharmazeutische Praeparate GmbH Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Passiflora incarnata “The purpose of this study is to evaluate the effects of Passiflora incarnata and Isoflavone combination in relieving the symptoms associated with Climacteric Syndrome.” NCT01695616
3

NCT02065843

NCT03780595

NCT01665170

Route Oral “Patients enrolled in this arm will take a tablet twice a day” NCT01695616